Abstract
Dopamine agonists are an important component of Parkinson's therapy. When weighing up the various therapy options, therapy with levodopa has recently been increasingly preferred due to its stronger efficacy and the ostensibly lower rate of side effects. The advantage of the lower incidence of motor complications during therapy with dopamine agonists was neglected. The occurrence of side effects can be explained by the different receptor affinity to the individual dopaminergic and non-dopaminergic receptors of the individual dopamine agonists. However, the different affinity to individual receptors also explains the different effect on individual Parkinson symptoms and can, therefore, contribute to a targeted use of the different dopamine agonists. Since comparative studies on the differential effect of dopamine agonists have only been conducted for individual substances, empirical knowledge of the differential effect is of great importance. Therefore, the guidelines for the treatment of Parkinson's disease do not consider the differential effect of the dopamine agonists. The historical consideration of dopamine agonists within Parkinson's therapy deserves special attention to be able to classify the current discussion about the significance of dopamine agonists.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
Data availability
Table citation should be withdrawn in this place. Data are available.
Change history
13 September 2023
A Correction to this paper has been published: https://doi.org/10.1007/s00702-023-02695-6
References
Agid Y (2001) Levodopa. Is toxicity a myth? 1998. Neurology 57:S46–S51
Alexander SPH, Christopoulos A, Davenport AP et al (2021) The concise guide to pharmacology 2021/22: G protein-coupled receptors. Br J Pharmacol 178:S27–S156. https://doi.org/10.1111/BPH.15538/FULL
Antonelli T, Fuxe K, Agnati L et al (2006) Experimental studies and theoretical aspects on A2A/D2 receptor interactions in a model of Parkinson’s disease. Relevance for L-dopa induced dyskinesias. J Neurol Sci 248:16–22. https://doi.org/10.1016/j.jns.2006.05.019
Baik JH, Picetti R, Saiardi A et al (1995) Parkinsonian-like locomotor impairment in mice lacking dopamine D2 receptors. Nature 377:424–428. https://doi.org/10.1038/377424A0
Barbeau A (1962) Parkinson’s disease. Union Med Can 91:539–540
Barcroft H, Schwab RS (1951) The effect of apomorphine and that of adrenalin, on the tremor of Parkinson’s disease. J Nerv Ment Dis 114:541–542
Bartl M, Dakna M, Schade S et al (2022) Longitudinal change and progression indicators using the movement disorder society-unified Parkinson’s disease rating scale in two independent cohorts with early Parkinson’s disease. J Parkinsons Dis 12:437–452. https://doi.org/10.3233/JPD-212860
Beaulieu M (1987) Clinical importance of D-1 and D-2 receptors. Can J Neurol Sci 14:402–406. https://doi.org/10.1017/s031716710003780x
Béreau M, Krack P, Brüggemann N, Münte TF (2019) Neurobiology and clinical features of impulse control failure in Parkinson’s disease. Neurol Res Pract. https://doi.org/10.1186/S42466-019-0013-5
Binde CD, Tvete IF, Gåsemyr JI et al (2020) Comparative effectiveness of dopamine agonists and monoamine oxidase type-B inhibitors for Parkinson’s disease: a multiple treatment comparison meta-analysis. Eur J Clin Pharmacol 76:1731–1743. https://doi.org/10.1007/S00228-020-02961-6
Birkmayer W, Hornykiewicz O (1961) The L-3,4-dioxyphenylalanine (DOPA)-effect in Parkinson-akinesia. Wien Klin Wochenschr 73:787–788
Bouthenet ML, Souil E, Martres MP et al (1991) Localization of dopamine D3 receptor mRNA in the rat brain using in situ hybridization histochemistry: comparison with dopamine D2 receptor mRNA. Brain Res 564:203–219. https://doi.org/10.1016/0006-8993(91)91456-B
Bunzow JR, van Tol HHM, Grandy DK et al (1988a) Cloning and expression of a rat D2 dopamine receptor cDNA. Nature 336:783–787. https://doi.org/10.1038/336783a0
Calne DB, Reid JL, Vakil SD et al (1971) Idiopathic Parkinsonism treated with an extracerebral decarboxylase inhibitor in combination with levodopa. Br Med J 3:729. https://doi.org/10.1136/BMJ.3.5777.729
Calne DB, Teychenne PF, Claveria LE et al (1974) Bromocriptine in parkinsonism. Br Med J 4:442–444. https://doi.org/10.1136/bmj.4.5942.442
Carlsson A, Lindqvist M, Magnusson T (1957) 3,4-dihydroxyphenylalanine and 5-hydroxytryptophan as reserpine antagonists. Nature 180:1200–1200. https://doi.org/10.1038/1801200a0
Cheshire P, Bertram K, Ling H et al (2014) Influence of single nucleotide polymorphisms in COMT, MAO-A and BDNF genes on dyskinesias and levodopa use in Parkinson’s disease. Neurodegener Dis 13:24–28. https://doi.org/10.1159/000351097
Chien EYT, Liu W, Zhao Q et al (2010) Structure of the human dopamine D3 receptor in complex with a D2/D3 selective antagonist. Science (1979) 330:1091–1095. https://doi.org/10.1126/science.1197410
Clarke CE, Speller J, Clarke JA (2000) Pramipexole versus bromocriptine for levodopa-induced complications in Parkinson’s disease. Cochrane Database Syst Rev. https://doi.org/10.1002/14651858.CD002259/MEDIA/CDSR/CD002259/IMAGE_N/NCD002259-CMP-001-14.PNG
Cotzias GC, Papavasiliou PS, Gellene R (1969) Modification of Parkinsonism–chronic treatment with L-dopa. N Engl J Med 280:337–345. https://doi.org/10.1056/NEJM196902132800701
de Lau LML, Verbaan D, Marinus J et al (2012) Catechol-O-methyltransferase Val158Met and the risk of dyskinesias in Parkinson’s disease. Mov Disord 27:132–135. https://doi.org/10.1002/MDS.23805
de Tosin MHS, Goetz CG, Luo S et al (2020) Item response theory analysis of the MDS-UPDRS motor examination: tremor vs. nontremor items. Mov Disord 35:1587–1595. https://doi.org/10.1002/mds.28110
Deutch AY (2006) Striatal plasticity in Parkinsonism: dystrophic changes in medium spiny neurons and progression in Parkinson’s disease. J Neural Transm. https://doi.org/10.1007/978-3-211-45295-0_12
Eckart C, Bunzeck N (2013) Dopamine modulates processing speed in the human mesolimbic system. Neuroimage 66:293–300. https://doi.org/10.1016/j.neuroimage.2012.11.001
Ehringer H, Hornykiewicz O (1960) Verteilung Von Noradrenalin Und Dopamin (3-Hydroxytyramin) Im Gehirn Des Menschen Und Ihr Verhalten Bei Erkrankungen Des Extrapyramidalen Systems. Klin Wochenschr 38:1236–1239. https://doi.org/10.1007/BF01485901/METRICS
Fahn S (1974) “On-off” phenomenon with levodopa therapy in parkinsonism. Neurology 24:431–431. https://doi.org/10.1212/WNL.24.5.431
Foltynie T, Cheeran B, Williams-Gray CH et al (2009) BDNF val66met influences time to onset of levodopa induced dyskinesia in Parkinson’s disease. J Neurol Neurosurg Psychiatry 80:141–144. https://doi.org/10.1136/JNNP.2008.154294
Fuxe K, Guidolin D, Agnati LF, Borroto-Escuela DO (2015) Dopamine heteroreceptor complexes as therapeutic targets in Parkinson’s disease. Expert Opin Ther Targets 19:377–398. https://doi.org/10.1517/14728222.2014.981529
Gerlach M, Double K, Arzberger T et al (2003) Dopamine receptor agonists in current clinical use: comparative dopamine receptor binding profiles defined in the human striatum. J Neural Transm 110:1119–1127. https://doi.org/10.1007/s00702-003-0027-5
Gershanik O, Heikkila RE, Duvoisin RC (1983) Behavioral correlations of dopamine receptor activation. Neurology 33:1489–1492. https://doi.org/10.1212/wnl.33.11.1489
Goetz CG (1998) Influence of COMT inhibition on levodopa pharmacology and therapy. Neurology. https://doi.org/10.1212/wnl.50.5_suppl_5.s26
Gottwald MD, Bainbridge JL, Dowling GA et al (1997) New pharmacotherapy for Parkinson’s disease. Ann Pharmacother 31:1205–1217. https://doi.org/10.1177/106002809703101014
Gray R, Ives N, Rick C et al (2014) Long-term effectiveness of dopamine agonists and monoamine oxidase B inhibitors compared with levodopa as initial treatment for Parkinson’s disease (PD MED): a large, open-label, pragmatic randomised trial. Lancet 384:1196–1205. https://doi.org/10.1016/S0140-6736(14)60683-8
Grosset KA, Grosset DG (2005) Patient-perceived involvement and satisfaction in Parkinson’s disease: effect on therapy decisions and quality of life. Mov Disord 20:616–619. https://doi.org/10.1002/mds.20393
Grosset KA, Bone I, Grosset DG (2005) Suboptimal medication adherence in Parkinson’s disease. Mov Disord 20:1502–1507. https://doi.org/10.1002/mds.20602
Guigoni C, Aubert I, Li Q et al (2005) Pathogenesis of levodopa-induced dyskinesia: focus on D1 and D3 dopamine receptors. Parkinsonism Relat Disord. https://doi.org/10.1016/j.parkreldis.2004.11.005
Hildick-Smith M (1976) Letter: alternatives to levodopa. Br Med J 1:1406. https://doi.org/10.1136/bmj.1.6022.1406
Hilger D, Masureel M, Kobilka BK (2018) Structure and dynamics of GPCR signaling complexes. Nat Struct Mol Biol 25:4–12. https://doi.org/10.1038/S41594-017-0011-7
Huang X, Lawler CP, Lewis MM et al (2001) D1 dopamine receptors. Int Rev Neurobiol 48:65–139. https://doi.org/10.1016/s0074-7742(01)48014-7
Huang X, Lewis MM, Jodi Van Scoy L et al (2020) The D 1 /D 5 dopamine partial agonist PF-06412562 in advanced stage Parkinson’s disease: a feasibility study HHS public access. J Parkinsons Dis 10:1515–1527. https://doi.org/10.3233/JPD-202188
Iravani MM, Haddon CO, Cooper JM et al (2006) Pramipexole protects against MPTP toxicity in non-human primates. J Neurochem 96:1315–1321. https://doi.org/10.1111/j.1471-4159.2005.03625.x
Jenner P, Taylor AR, Campbell DB (1973) Letter: preliminary investigation of the metabolism of piribedil (ET 495); a new central dopaminergic agonist and potential anti-parkinson agent. J Pharm Pharmacol 25:749–750. https://doi.org/10.1111/J.2042-7158.1973.TB10060.X
Jones-Tabah J, Mohammad H, Paulus EG et al (2022) The signaling and pharmacology of the dopamine D1 receptor. Front Cell Neurosci. https://doi.org/10.3389/FNCEL.2021.806618
Jost WH, Buhmann C, Classen J et al (2022) Relevance of COMT inhibitors in the treatment of motor fluctuations. Nervenarzt 93:1035–1045. https://doi.org/10.1007/S00115-021-01237-3
Kaplan N, Vituri A, Korczyn AD et al (2014) Sequence variants in SLC6A3, DRD2, and BDNF genes and time to levodopa-induced dyskinesias in Parkinson’s disease. J Mol Neurosci 53:183–188. https://doi.org/10.1007/S12031-014-0276-9
Kebabian JW, Calne DB (1979) Multiple receptors for dopamine. Nature 277:93–96. https://doi.org/10.1038/277093a0
Klicken oder tippen Sie hier, um Text einzugeben.
Kurlan R, Rothfield KP, Woodward WR et al (1988) Erratic gastric emptying of levodopa may cause “random” fluctuations of parkinsonian mobility. Neurology 38:419–421. https://doi.org/10.1212/wnl.38.3.419
Kurth MC, Adler CH (1998) COMT inhibition: a new treatment strategy for Parkinson’s disease. Neurology. https://doi.org/10.1212/wnl.50.5_suppl_5.s3
Li BD, Cui JJ, Song J et al (2018) Comparison of the efficacy of different drugs on non-motor symptoms of Parkinson’s disease: a network meta-analysis. Cell Physiol Biochem 45:119–130. https://doi.org/10.1159/000486252
Lieberman AN, Leibowitz M, Neophytides A et al (1979) Pergolide and lisuride for Parkinson’s disease. Lancet 2:1129–1130. https://doi.org/10.1016/S0140-6736(79)92524-8
Luo S, Zou H, Stebbins GT et al (2022) Dissecting the domains of Parkinson’s disease: insights from longitudinal item response theory modeling. Mov Disord 37:1904–1914. https://doi.org/10.1002/MDS.29154
Mailman RB, Nichols DE, Williams M (1998) Dopamine D1 receptor agonists as antiparkinson drugs [3] (multiple letters). Trends Pharmacol Sci 19:255–256. https://doi.org/10.1016/S0165-6147(98)01219-X
Marsden CD, Parkes JD (1977) Success and problems of long-term levodopa therapy in Parkinson`s disease. Lancet 309:345–349. https://doi.org/10.1016/S0140-6736(77)91146-1
Martini ML, Ray C, Yu X et al (2019) Designing functionally selective noncatechol dopamine D1 receptor agonists with potent in vivo antiparkinsonian activity. ACS Chem Neurosci 10:4160–4182. https://doi.org/10.1021/ACSCHEMNEURO.9B00410
Masellis M, Collinson S, Freeman N et al (2016) Dopamine D2 receptor gene variants and response to rasagiline in early Parkinson’s disease: a pharmacogenetic study. Brain 139:2050–2062. https://doi.org/10.1093/BRAIN/AWW109
Millan MJ (2010a) From the cell to the clinic: a comparative review of the partial D2/D3 receptor agonist and α2-adrenoceptor antagonist, piribedil, in the treatment of Parkinson’s disease. Pharmacol Ther 128:229–273. https://doi.org/10.1016/j.pharmthera.2010.06.002
Millan MJ, Maiofiss L, Cussac D et al (2002) Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. I. A multivariate analysis of the binding profiles of 14 drugs at 21 native and cloned human receptor subtypes. J Pharmacol Exp Ther 303:791–804. https://doi.org/10.1124/jpet.102.039867
Muhlack S, Herrmann L, Salmen S, Müller T (2014) Fewer fluctuations, higher maximum concentration and better motor response of levodopa with catechol-O-methyltransferase inhibition. J Neural Transm 121:1357–1366. https://doi.org/10.1007/s00702-014-1213-3
Newman-Tancredi A, Cussac D, Audinot V et al (2002a) Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. II. Agonist and antagonist properties at subtypes of dopamine D2-like receptor and α1/α2-adrenoceptor. J Pharmacol Exp Ther 303:805–814. https://doi.org/10.1124/jpet.102.039875
Newman-Tancredi A, Cussac D, Quentric Y et al (2002b) Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. III. Agonist and antagonist properties at serotonin, 5-HT1 and 5-HT2, receptor subtypes. J Pharmacol Exp Ther 303:815–822. https://doi.org/10.1124/jpet.102.039883
Nyholm D, Lennernäs H (2008) Irregular gastrointestinal drug absorption in Parkinson’s disease. Expert Opin Drug Metab Toxicol 4:193–203. https://doi.org/10.1517/17425255.4.2.193
Oliveri RL, Annesi G, Zappia M et al (1999) Dopamine D2 receptor gene polymorphism and the risk of levodopa-induced dyskinesias in PD. Neurology 53:1425–1430. https://doi.org/10.1212/wnl.53.7.1425
Ong WY, Leow DMK, Herr DR, Yeo CJJ (2022) What do randomized controlled trials inform us about potential disease-modifying strategies for Parkinson’s disease? Neuromolecular Med. https://doi.org/10.1007/S12017-022-08718-X
Parkinson Study Group CALM Cohort Investigators (2009) Long-term effect of initiating pramipexole vs levodopa in early Parkinson disease. Arch Neurol 66:563–570. https://doi.org/10.1001/ARCHNEUR.66.1.NCT90001
Parkinson’s Disease Research Group in the United Kingdom (1993) Comparisons of therapeutic effects of levodopa, levodopa and selegiline, and bromocriptine in patients with early, mild Parkinson’s disease: three year interim report. BMJ 307:469–472. https://doi.org/10.1136/BMJ.307.6902.469
Quinn N, Critchley P, Parkes D et al (1986) When should levodopa be started? Lancet 328(8513):985–986
Rajput AH, Stern W, Laverty WH (1984) Chronic low-dose levodopa therapy in Parkinson’s disease: an argument for delaying levodopa therapy. Neurology 34:991–996. https://doi.org/10.1212/WNL.34.8.991
Riederer P (1988) Factors contributing to fluctuations of the dopaminergic nigro-striatal feedback system in Parkinson’s disease. J Neural Transm Suppl 27:191–199. https://doi.org/10.1007/978-3-7091-8954-2_16
Riesenberg R, Werth J, Zhang Y et al (2020) PF-06649751 efficacy and safety in early Parkinson’s disease: a randomized, placebo-controlled trial. Ther Adv Neurol Disord. https://doi.org/10.1177/1756286420911296
Rodríguez-Violante M, Ospina-García N, Dávila-Avila NM et al (2018) Motor and non-motor wearing-off and its impact in the quality of life of patients with Parkinson’s disease. Arq Neuropsiquiatr 76:517–521. https://doi.org/10.1590/0004-282x20180074
Roth BL (2007) Drugs and valvular heart disease. N Engl J Med 356:6–9. https://doi.org/10.1056/NEJMP068265
Schachter M, Blackstock J, Dick JPR et al (1979) Lisuride in Parkinson’s disease. Lancet 2:1129. https://doi.org/10.1016/S0140-6736(79)92523-6
Schade R, Andersohn F, Suissa S et al (2007) Dopamine agonists and the risk of cardiac-valve regurgitation. N Engl J Med 356:29–38. https://doi.org/10.1056/NEJMOA062222
Schapira AHV, McDermott MP, Barone P et al (2013) Pramipexole in patients with early Parkinson’s disease (PROUD): a randomised delayed-start trial. Lancet Neurol 12:747–755. https://doi.org/10.1016/S1474-4422(13)70117-0
Scheller D, Ullmer C, Berkels R et al (2009) The in vitro receptor profile of rotigotine: a new agent for the treatment of Parkinson’s disease. Naunyn Schmied Arch Pharmacol 379:73–86. https://doi.org/10.1007/s00210-008-0341-4
Schuepbach WMM, Rau J, Knudsen K et al (2013) Neurostimulation for Parkinson’s disease with early motor complications. N Engl J Med 368:610–622. https://doi.org/10.1056/NEJMOA1205158
Schwab RS, Amador LV, Lettvin JY (1951) Apomorphine in Parkinson’s disease. Trans Am Neurol Assoc 56:251–253. https://doi.org/10.1097/01.wnf.0000171195.68116.d0
Schwabe U (2008) Parkinsonmittel. Arzneiverordnungs-Report 2007:761–773. https://doi.org/10.1007/978-3-540-72548-0_41
Seeman P (2015) Parkinson’s disease treatment may cause impulse-control disorder via dopamine D3 receptors. Synapse 69:183–189. https://doi.org/10.1002/syn.21805
Seeman P, van Tol HHM (1994) Dopamine receptor pharmacology. Trends Pharmacol Sci 15:264–270. https://doi.org/10.1016/0165-6147(94)90323-9
Sheng Y, Zhou X, Yang S et al (2021) Modelling item scores of unified Parkinson’s disease rating scale part III for greater trial efficiency. Br J Clin Pharmacol 87:3608–3618. https://doi.org/10.1111/bcp.14777
Shi L, Javitch JA (2002) The binding site of aminergic G protein-coupled receptors: the transmembrane segments and second extracellular loop. Annu Rev Pharmacol Toxicol 42:437–467. https://doi.org/10.1146/annurev.pharmtox.42.091101.144224
Sibley DR, Monsma FJ (1992) Molecular biology of dopamine receptors. Trends Pharmacol Sci 13:61–69. https://doi.org/10.1016/0165-6147(92)90025-2
Stibe CMH, Kempster PA, Lees AJ, Stern GM (1988) Subcutaneous apomorphine in Parkinsonian on-off oscillations. Lancet 331:403–406. https://doi.org/10.1016/S0140-6736(88)91193-2
Stocchi F, Rascol O, Kieburtz K et al (2010) Initiating levodopa/carbidopa therapy with and without entacapone in early Parkinson disease: the STRIDE-PD study. Ann Neurol 68:18–27. https://doi.org/10.1002/ANA.22060
Stowe R, Ives N, Clarke CE et al (2011) Meta-analysis of the comparative efficacy and safety of adjuvant treatment to levodopa in later Parkinson’s disease. Mov Disord 26:587–598. https://doi.org/10.1002/mds.23517
Tinsley RB, Bye CR, Parish CL et al (2009) Dopamine D2 receptor knockout mice develop features of Parkinson disease. Ann Neurol 66:472–484. https://doi.org/10.1002/ANA.21716
Vaillancourt DE, Schonfeld D, Kwak Y et al (2013) Dopamine overdose hypothesis: evidence and clinical implications. Mov Disord 28:1920–1929. https://doi.org/10.1002/mds.25687
van Holstein M, Aarts E, van der Schaaf ME et al (2011) Human cognitive flexibility depends on dopamine D2 receptor signaling. Psychopharmacology 218:567–578. https://doi.org/10.1007/s00213-011-2340-2
Wang J, Liu ZL, Chen B (2001) Dopamine D5 receptor gene polymorphism and the risk of levodopa-induced motor fluctuations in patients with Parkinson’s disease. Neurosci Lett 308:21–24. https://doi.org/10.1016/S0304-3940(01)01971-1
Wang S, Wacker D, Levit A et al (2017) D4 dopamine receptor high-resolution structures enable the discovery of selective agonists. Science 358:381–386. https://doi.org/10.1126/SCIENCE.AAN5468
Wang S, Che T, Levit A et al (2018a) Structure of the D2 dopamine receptor bound to the atypical antipsychotic drug risperidone. Nature 555:269–273. https://doi.org/10.1038/nature25758
Wang Y, Yu X, Zhang P et al (2018b) Neuroprotective effects of pramipexole transdermal patch in the MPTP-induced mouse model of Parkinson’s disease. J Pharmacol Sci 138:31–37. https://doi.org/10.1016/j.jphs.2018.08.008
Watanabe AM, Chase TN, Cardon PV (1970) Effect of L-dopa alone and in combination with an extracerebral decarboxylase inhibitor on blood pressure and some cardiovascular reflexes. Clin Pharmacol Ther 11:740–746. https://doi.org/10.1002/CPT1970115740
Wei SZ, Yao XY, Wang CT et al (2021) Pramipexole regulates depression-like behavior via dopamine D3 receptor in a mouse model of Parkinson’s disease. Brain Res Bull 177:363–372. https://doi.org/10.1016/J.BRAINRESBULL.2021.10.015
Wilson SM, Wurst MG, Whatley MF, Daniels RN (2020) Classics in chemical neuroscience: pramipexole. ACS Chem Neurosci 11:2506–2512. https://doi.org/10.1021/ACSCHEMNEURO.0C00332/ASSET/IMAGES/LARGE/CN0C00332_0002.JPEG
Yin J, Chen KYM, Clark MJ et al (2020) Structure of a D2 dopamine receptor-G-protein complex in a lipid membrane. Nature 584:125–129. https://doi.org/10.1038/S41586-020-2379-5
Yokochi M (2007) Mesolimbic and mesocortical pathways in Parkinson disease. Brain Nerve 59:943–951
Zanettini R, Antonini A, Gatto G et al (2007) Valvular heart disease and the use of dopamine agonists for Parkinson’s disease. N Engl J Med 356:39–46. https://doi.org/10.1056/NEJMOA054830
Zhang J, Xiong B, Zhen X, Zhang A (2009) Dopamine D1 receptor ligands: where are we now and where are we going. Med Res Rev 29:272–294. https://doi.org/10.1002/med.20130
Zhang YH, Tang BS, Song CY et al (2013) The relationship between the phenotype of Parkinson’s disease and levodopa-induced dyskinesia. Neurosci Lett 556:109–112. https://doi.org/10.1016/J.NEULET.2013.10.018
Zis P, Grünewald RA, Chaudhuri RK, Hadjivassiliou M (2017) Peripheral neuropathy in idiopathic Parkinson’s disease: a systematic review. J Neurol Sci 378:204–209. https://doi.org/10.1016/j.jns.2017.05.023
Zou H, Aggarwal V, Stebbins GT et al (2022) Application of longitudinal item response theory models to modeling Parkinson’s disease progression. CPT Pharmacometrics Syst Pharmacol 11:1382–1392. https://doi.org/10.1002/psp4.12853
Author information
Authors and Affiliations
Corresponding author
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Woitalla, D., Buhmann, C., Hilker-Roggendorf, R. et al. Role of dopamine agonists in Parkinson's disease therapy. J Neural Transm 130, 863–873 (2023). https://doi.org/10.1007/s00702-023-02647-0
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00702-023-02647-0